Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Tandem Diabetes Care’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001438133-26-000125
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Gross profit | 144,780 | 125,855 | 281,568 | 244,262 |
| Operating expenses: | ||||
| Selling, general and administrative | 111,642 | 109,596 | 219,829 | 223,449 |
| Research and development | 46,930 | 48,118 | 92,965 | 98,333 |
| Acquired in-process research and development expenses | — | — | — | 75,217 |
| Litigation and settlement expense | — | 19,951 | — | 19,951 |
| Total operating expenses | 158,572 | 177,665 | 312,794 | 416,950 |
| Operating loss | (13,792) | (51,810) | (31,226) | (172,688) |
Item 1. Financial Statements.
FAQ
- What is Tandem Diabetes Care's R&D?
- Tandem Diabetes Care (TNDM) reported R&D of $46.93M in Q2 2026.
- How has Tandem Diabetes Care's R&D changed year-over-year?
- Tandem Diabetes Care's R&D decreased by 2.5% year-over-year, from $48.12M to $46.93M.
- What is the long-term trend for Tandem Diabetes Care's R&D?
- Over 4 years (2021 to 2025), Tandem Diabetes Care's R&D has grown at a 20.3% compound annual growth rate (CAGR), from $92.05M to $193.11M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Tandem Diabetes Care's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude